Recent Therapeutic Advances and Updates in the Management of MSI-H Colorectal Cancer: A Closer Look at the Evolving Role of Immunotherapy

A continuing medical education activity provided by NAMCP and AAMCN

Recent Therapeutic Advances and Updates in the Management of MSI-H Colorectal Cancer: A Closer Look at the Evolving Role of Immunotherapy is a two-part webinar series

This is Part 2 of the series focusing on the management and treatment of colorectal cancer.

This activity is an archive from the webinar held February 26, 2021

This activity is valid from March 1, 2021 to March 1, 2023
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.

Description:
Colorectal cancer (CRC) is the development of cancer from the colon or rectum, due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Excluding skin cancers, CRC is the third most common cancer diagnosed in both men and women in the United States. In 2021, it is expected that there will be 149,500 new cases of colorectal cancer and 52,980 deaths. When discovered early, CRC is highly treatable. However, when the disease has spread, treatment becomes much more difficult. Fortunately, immunotherapy options have become available for patients with metastatic CRC, particular in MSI-High disease, giving clinicians and managed care professionals more options in managing this patient population.

Upon completion of this activity, participants will be able to:

  • Identify current unmet clinical and economic needs in the management of MSI-H colorectal cancer and evidence-based recommendations for the care of patients with these tumors

  • Use results of MSI/dMMR testing to determine appropriate management of advanced CRC

  • Examine recent clinical data on the safety and efficacy of immune checkpoint inhibitors in the first-line management of MSI-H colorectal cancer in the first line setting

  • Examine evidence-based strategies to monitor for, recognize, and effectively manage potential irAEs associated with immune checkpoint inhibition in MSI-H colorectal cancer

  • Identify patients with MSI-H colorectal cancer who would potentially benefit from immunotherapies, in first-line settings or beyond

     

Faculty: Richard Kim, MD
Section Chief of GI Medical Oncology, Moffitt Cancer Center
Associate Professor, Division of Medical Oncology
University of South Florida College of Medicine

Disclosure:

Dr. Kim has served as a consultant for Merck, Taiho, BMS, and Pfizer. He has served as a speaker for Lilly and Incyte. He has served as a researcher for BMS and Eisai. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue